PCA3 and posterior cortical atrophy: Novel biomarkers, such as the precursor isoform [-2]proPSA (p2PSA) and the Prostate Cancer Antigen 3 (PCA3), also perform better than serum PSA and have further, but not dramatically, increased the accuracy of PCa risk prediction models (4, 5).